Close

WHO Authorizes PAXLOVID, The First Oral COVID-19 Generic

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

The generic version of the COVID-19 oral antiviral therapy candidate nirmatrelvir has been approved by the World Health Organization Prequalification of Medicines Program (WHO PQ), as stated by the Indian pharmaceutical company Hetero.

This is the first prequalification for a generic form of PAXLOVID, an oral antiviral medicine manufactured by Pfizer and designated by the WHO as the best therapeutic option available for high-risk patients. Nirmatrelvir and ritonavir were strongly advised by the WHO for mild and moderate COVID-19 patients who were at the greatest risk of being admitted to the hospital, such as those who were immunosuppressed, elderly, or hadn’t had a vaccine.

Nirmatrelvir 150 mg (2 pills) and ritonavir 100 mg are both included in the combo pack, which Hetero is marketing as NIRMACOM (1 tablet). Only by prescription, it must be started within five days after the onset of symptoms and as soon as COVID-19 has been diagnosed. The production of NIRMACOM will take place at Hetero’s facilities in India.

In order to produce and market a generic version of Pfizer’s COVID-19 oral antiviral therapy candidate, nirmatrelvir, in low- and middle-income nations, Hetero engaged in a non-exclusive voluntary licencing agreement with Medicines Patent Pool.

Latest stories

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back